Optimising Frontline Treatment for Improved Outcomes in Lower-Risk MDS

This session is organised and funded by Bristol Myers Squibb. This session is a scientific presentation and discussion for the purpose of scientific exchange. The presenters can express their own opinions that may differ from the standpoint of Bristol Myers Squibb.  

Neither the session nor the information presented or discussed is for the promotional purpose of influencing prescribing or treatment decisions. Prescribing decisions are made by healthcare professionals. Always refer to the approved product labelling before prescribing (e.g., SmPC, US Prescribing Information). 

This lower-risk myelodysplastic syndromes symposium recorded at the European Hematology Association (EHA) Congress 2026, held between 11^th–14^th June, 2026, in Stockholm, Sweden, provided an overview of emerging data from pivotal trials and real-world evidence to help shape strategies for improving patient care and optimising outcomes. Hear experts review the unmet needs and burden of anaemia, discuss long-term efficacy data and treatment-optimisation strategies, highlight advantages of earlier intervention, and explore evidence for clinical benefits beyond haemoglobin improvement.

1. Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA
2. Nice University Hospital, Côte d’Azur University, Nice, France
3. DMSC, Hematology, AOU Careggi, University of Florence, Italy
4. New York-Presbyterian Hospital, Weill Cornell Medicine New York, USA

Zeidan has served on advisory boards or clinical trial committees and/or received honoraria from AbbVie, Akesobio, Agios, Amgen, Astellas, AstraZeneca/Alexion, BeOne, BioCryst, BioThera, Boehringer Ingelheim, Celgene/BMS, Chiesi/Cornerstone BioPharma, Daiichi Sankyo, Dr Reddy’s Laboratories, Epizyme, Faron, FibroGen/Kyntra Bio, Genentech/Roche, Geron, Gilead, GlycoMimetics, GSK, InnoCare, Janssen/J&J, Jasper, Karyopharm, Keros Therapeutics, Kura Oncology, Kyowa Kirin, Notable, Novartis, Oncoverity, Orum, Otsuka, Pfizer, PureTech/Gallop Oncology, Regeneron, Rigel, Schrödinger, Seattle Genetics, Servier, Shattuck Labs, Sumitomo, Syndax, Syros, Taiho, Takeda, Treadwell, Vincerx, and Zentalis; and received institutional clinical trial support from AbbVie, Agios, Akesobio, Astex/Taiho, BMS/Celgene, Daiichi Sankyo, Faron, Genentech/Roche, Geron, GSK, Kura, InnoCare, Novartis, Oncoverity, Orum, Shattuck Labs, SillaJen, Syros, SystImmune, and Takeda.

Cluzeau has served on advisory boards for AbbVie, Arog Pharmaceuticals, BMS, Jazz Pharmaceuticals, Novartis, and Servier; received payments for clinical research from Amgen, Arog Pharmaceuticals, BMS, Janssen, Keros Therapeutics, Novartis, Servier, Syros, and Takeda; education payments from BMS, Jazz Pharmaceuticals, Incyte, Novartis, and Servier; and payments for international congresses from AbbVie, BMS, Novartis, Pfizer, and Servier.

Santini has served on advisory boards for Alexion, Ascentage, BMS, Faron, Geron, GSK, Novartis, Pfizer, Servier, and Takeda.

Desai has served on advisory boards for BMS, Janssen, Kura Oncology, and Rigel; and received payments for clinical research from BMS, Karius, and Geron.